[Public Notice+] Cellivery Obtains US Patent for Parkinson's Disease Treatment

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 13th that its Parkinson's disease treatment new drug iCP-Parkin has succeeded in registering a patent in the United States, following Australia, the European Union (EU), and Japan. This result came after two years of examination by the United States Patent and Trademark Office, recognizing novelty and inventiveness.

Daewoong Cho, CEO of Cellivery, stated, "Until now, the existing theory was that 'once Parkinson's disease occurs, treatment is impossible,' but we have made a significant discovery by developing a new drug that can restore motor and cognitive functions to pre-onset levels." He added, "The patent examination evaluated whether recovery to the actual pre-onset level, as we claim, is indeed possible."

He continued, "At the same time, our work is currently under review for over a year in the top scientific journals in this field. If our claims are recognized by the academic community, severe neurodegenerative diseases represented by Parkinson's disease, Alzheimer's disease, and other dementias will move beyond merely slowing disease progression or alleviating symptoms." He emphasized, "Being acknowledged by the mainstream science community that recovery treatment to normal levels before disease onset is possible would be a groundbreaking discovery."

The Parkinson's disease treatment iCP-Parkin has been patented in 34 major countries worldwide, including the 27 EU member states. Among these, it succeeded in patent registration in the United States, where examination is the most stringent and registration is difficult. It is currently registered in 30 countries, including Australia, Europe, and Japan. Additionally, examinations are underway in China, Canada, South Korea, and India.

CEO Cho emphasized, "The Parkinson's disease treatment iCP-Parkin, which has completed U.S. patent registration, is one of Cellivery's major new drug development pipelines," adding, "It will be a great asset in negotiations with global pharmaceutical companies based in the United States, which occupy the largest part of the pharmaceutical market, as well as with most pharmaceutical companies seeking licensing (L/O) rights in the U.S. region."

This content was produced with the assistance of AI translation services.